Ocugen to Present at the H.C. Wainwright 22nd Annual Global Investment Conference
September 03 2020 - 6:30AM
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on
discovering, developing, and commercializing transformative
therapies to cure blindness diseases, today announced it will
present at the H.C. Wainwright 22nd Annual Global Investment
Conference on Tuesday, September 15 at 3 p.m. ET.
Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder
will present virtually to provide an update on the development of
Ocugen’s breakthrough modifier gene therapy platform as well as its
novel biologic product candidate. He will highlight Ocugen’s
lead product candidate, OCU400, which has the potential to treat
many forms of retinitis pigmentosa and just received its fourth FDA
orphan drug designation. Dr. Musunuri will share Ocugen’s recent
accomplishments and its upcoming planned near and medium-term
milestones.
Presentation
Details:Date: Tuesday, September 15,
2020Time: 03:00 PM (Eastern Time)Webcast
Link: https://wsw.com/webcast/hcw7/ocgn/1597167
The H.C. Wainwright 22nd Annual Global Investment
Conference will take place on September 14-16 virtually.
About Ocugen, Inc. Ocugen, Inc. is
a biopharmaceutical company focused on discovering, developing, and
commercializing transformative therapies to cure blindness
diseases. Our breakthrough modifier gene therapy platform has the
potential to treat multiple retinal diseases with one drug – “one
to many” and our novel biologic product candidate aims to offer
better therapy to patients with underserved diseases such as wet
age-related macular degeneration, diabetic macular edema, and
diabetic retinopathy. For more information, please visit
www.ocugen.com.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995, which are subject to risks and uncertainties.
We may, in some cases, use terms such as “predicts,” “believes,”
“potential,” “proposed,” “continue,” “estimates,” “anticipates,”
“expects,” “plans,” “intends,” “may,” “could,” “might,” “will,”
“should” or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from our current expectations. These and other risks and
uncertainties are more fully described in our periodic filings with
the Securities and Exchange Commission (the “SEC”), including the
risk factors described in the section entitled “Risk Factors” in
the quarterly and annual reports that we file with the SEC. Any
forward-looking statements that we make in this press release speak
only as of the date of this press release. Except as required by
law, we assume no obligation to update forward-looking statements
contained in this press release whether as a result of new
information, future events or otherwise, after the date of this
press release.
Corporate Contact:Ocugen,
Inc.Sanjay SubramanianChief Financial Officer ir@ocugen.com
Media
Contact:LaVoieHealthScienceEmmie
Twomblyetwombly@lavoiehealthscience.com+1 857-389-6042
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From Apr 2024 to May 2024
Ocugen (NASDAQ:OCGN)
Historical Stock Chart
From May 2023 to May 2024